Close Menu

NEW YORK (GenomeWeb) – Invitae reported after the close of the market Tuesday that its fourth quarter 2018 revenues increased 78 percent from the prior year.

For the three months ended Dec. 31, 2018, Invitae reported $45.4 million in revenues compared to $25.4 million in Q4 2017, beating the consensus Wall Street estimate of $40.8 million. Invitae reported testing revenue of $44.5 million for the quarter, which includes $1.9 million in payments from Medicare for Lynch syndrome analysis, as well as $810,000 in other revenue.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.